Shopping Cart
- Remove All
- Your shopping cart is currently empty
Urabrelimab (SRF-231) is a humanized antibody targeting CD47, with antitumor activity. It blocks the CD47-SIRPα interaction and is used in studies of advanced malignant solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $198 | In Stock | |
5 mg | $579 | In Stock | |
10 mg | $928 | In Stock | |
25 mg | $1,370 | In Stock | |
50 mg | $1,850 | In Stock |
Description | Urabrelimab (SRF-231) is a humanized antibody targeting CD47, with antitumor activity. It blocks the CD47-SIRPα interaction and is used in studies of advanced malignant solid tumors. |
In vitro | Urabrelimab specifically binds to human CD47 to induce phagocytosis in malignant B-cell lymphoma. Urabrelimab (10 μg/mL) induced tumor cell death in a CD32A-dependent manner. [1] |
In vivo | Urabrelimab(100 μg, 3 times/week for 3 weeks) showed antitumor activity in a range of blood tumor xenotransplantation models. [1] |
Alias | SRF-231, SRF231 |
Cas No. | 2249722-58-3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.